deferoxamine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
792 70-51-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • deferoxamine
  • deferoxamine mesylate
  • deferoxamin
  • desferrioxamine
  • desferrioxamine mesilate
  • deferoxamine mesilate
  • desferrioxamine mesylate
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
  • Molecular weight: 560.69
  • Formula: C25H48N6O8
  • CLOGP: -0.18
  • LIPINSKI: 3
  • HAC: 14
  • HDO: 6
  • TPSA: 205.84
  • ALOGS: -3.75
  • ROTB: 23

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 178.35 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 5 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.35 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.33 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.05 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 1, 1968 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Serum ferritin increased 222.33 22.76 50 2081 5152 50597841
Laryngitis fungal 86.49 22.76 13 2118 134 50602859
Mucormycosis 64.65 22.76 16 2115 2467 50600526
Sickle cell anaemia with crisis 55.07 22.76 16 2115 4527 50598466
Bacterial sepsis 49.51 22.76 14 2117 3598 50599395
Liver iron concentration increased 40.61 22.76 5 2126 8 50602985
Iron overload 36.48 22.76 8 2123 727 50602266
Haemoglobin decreased 34.38 22.76 34 2097 127182 50475811
Haemosiderosis 33.25 22.76 6 2125 200 50602793
Infective chondritis 29.87 22.76 4 2127 16 50602977
Blood creatinine increased 29.66 22.76 25 2106 76135 50526858
Transplant failure 26.35 22.76 7 2124 1426 50601567
Maculopathy 24.13 22.76 7 2124 1967 50601026
Injection site abscess 23.52 22.76 6 2125 1043 50601950
Caesarean section 23.52 22.76 12 2119 15627 50587366
Thalassaemia beta 23.33 22.76 3 2128 8 50602985

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Serum ferritin increased 171.91 22.71 45 1914 5543 29567025
Blood iron increased 37.28 22.71 9 1950 792 29571776
Spinal X-ray abnormal 34.49 22.71 4 1955 0 29572568
Liver iron concentration increased 30.83 22.71 4 1955 6 29572562
Visual acuity reduced 29.64 22.71 16 1943 14860 29557708
Iron overload 29.29 22.71 8 1951 1147 29571421
Blood creatinine increased 27.65 22.71 31 1928 85071 29487497

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Serum ferritin increased 288.60 21.10 70 3161 8398 64487103
Fundoscopy abnormal 138.91 21.10 18 3213 41 64495460
Laryngitis fungal 77.37 21.10 12 3219 128 64495373
Mucormycosis 60.35 21.10 20 3211 7321 64488180
Spinal X-ray abnormal 51.68 21.10 7 3224 25 64495476
Liver iron concentration increased 47.92 21.10 6 3225 9 64495492
Visual acuity reduced 46.34 21.10 24 3207 27117 64468384
Sickle cell anaemia with crisis 45.72 21.10 15 3216 5317 64490184
Iron overload 43.50 21.10 11 3220 1551 64493950
Haemoglobin decreased 38.40 21.10 48 3183 195015 64300486
Agranulocytosis 36.16 21.10 23 3208 38206 64457295
Maculopathy 33.96 21.10 10 3221 2486 64493015
Bacterial sepsis 33.54 21.10 13 3218 7444 64488057
Blood creatinine increased 30.92 21.10 36 3195 135746 64359755
Blood iron increased 30.11 21.10 8 3223 1369 64494132
Myelodysplastic syndrome 29.63 21.10 18 3213 27561 64467940
Haemosiderosis 28.00 21.10 6 3225 410 64495091
Infective chondritis 26.93 21.10 4 3227 31 64495470
Haemochromatosis 25.95 21.10 7 3224 1267 64494234
Optic neuropathy 23.93 21.10 8 3223 3003 64492498
Retinopathy 23.06 21.10 8 3223 3357 64492144
Foetal distress syndrome 22.01 21.10 5 3226 447 64495054
Thalassaemia beta 21.69 21.10 3 3228 13 64495488

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V03AC01 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Iron chelating agents
FDA MoA N0000000144 Iron Chelating Activity
FDA EPC N0000175522 Iron Chelator
CHEBI has role CHEBI:26672 siderochromes
CHEBI has role CHEBI:38157 iron chelating agents
CHEBI has role CHEBI:173084 ferroptosis inhibitors
MeSH PA D002614 Chelating Agents
MeSH PA D007502 Iron Chelating Agents
MeSH PA D064449 Sequestering Agents
MeSH PA D017262 Siderophores
CHEBI has role CHEBI:50247 antidotes

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Poisoning by iron AND/OR its compounds indication 55381001
Chronic Iron Overload indication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.38 acidic
pKa2 8.99 acidic
pKa3 9.53 acidic
pKa4 13.04 acidic
pKa5 13.65 acidic
pKa6 10.56 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Hypoxia-inducible factor 1-alpha Transcription factor EC50 4.75 CHEMBL
Deoxyhypusine hydroxylase Enzyme IC50 5.30 CHEMBL

External reference:

IDSource
4019705 VUID
N0000147797 NUI
D01186 KEGG_DRUG
138-14-7 SECONDARY_CAS_RN
3131 RXNORM
4018789 VANDF
4019705 VANDF
C0011145 UMLSCUI
CHEBI:4356 CHEBI
CHEMBL556 ChEMBL_ID
CHEMBL1234 ChEMBL_ID
D003676 MESH_DESCRIPTOR_UI
DB00746 DRUGBANK_ID
1682 INN_ID
J06Y7MXW4D UNII
2973 PUBCHEM_CID
4539 MMSL
46738 MMSL
d01402 MMSL
001089 NDDF
004540 NDDF
372825006 SNOMEDCT_US
387224002 SNOMEDCT_US
70702006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Desferal HUMAN PRESCRIPTION DRUG LABEL 1 0078-0467 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR NDA 19 sections
Deferoxamine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-2336 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 19 sections
Deferoxamine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0409-2337 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 19 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 47781-623 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 12 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 47781-624 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 12 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 52609-4504 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 11 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 52609-4505 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 11 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60505-6236 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 11 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60505-6237 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 11 sections
Deferoxamine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 60505-6238 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 12 sections
Deferoxamine Human Prescription Drug Label 1 63323-597 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 95 mg INTRAVENOUS ANDA 17 sections
Deferoxamine Human Prescription Drug Label 1 63323-599 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 95 mg INTRAVENOUS ANDA 17 sections
Deferoxamine mesylate Human Prescription Drug Label 1 68083-172 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAMUSCULAR ANDA 11 sections
Deferoxamine mesylate Human Prescription Drug Label 1 68083-173 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 11 sections